{
    "Rank": 1033,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00006017",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CWRU1599"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "U01CA063200",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/U01CA063200"
                        },
                        {
                            "SecondaryId": "P30CA043703",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA043703"
                        },
                        {
                            "SecondaryId": "CWRU-1599"
                        },
                        {
                            "SecondaryId": "NCI-91"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Case Comprehensive Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer",
                "OfficialTitle": "A Randomized Phase II Trial of Two Different Schedules of Administration of Rebeccamycin Analog in Patients With Advanced Non-Small Cell Lung Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "June 2010",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "May 2000"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "July 2003",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "January 2005",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "July 5, 2000",
                "StudyFirstSubmitQCDate": "January 26, 2003",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "January 27, 2003",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "June 9, 2010",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 10, 2010",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Afshin Dowlati, MD",
                    "ResponsiblePartyOldOrganization": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Case Comprehensive Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of rebeccamycin analogue is more effective in treating non-small cell lung cancer.\n\nPURPOSE: Randomized phase II trial to compare the effectiveness of two rebeccamycin analogue regimens in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nCompare the efficacy, in terms of response rate, in patients with advanced or recurrent non-small cell lung cancer treated with rebeccamycin analogue via 1 infusion vs 5 daily infusions every 3 weeks.\nCompare the response duration in patients treated with these regimens.\nCompare the toxicity profiles of these two regimens in these patients.\n\nOUTLINE: This is a randomized, multicenter study. Patients are stratified according to performance status (0 or 1 vs 2) and participating center. Patients are randomized to one of two treatment arms.\n\nArm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1.\nArm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.\n\nPatients are followed every 3 months.\n\nPROJECTED ACCRUAL: A total of 36-64 patients (18-32 per arm) will be accrued for this study at a rate of 3-4 patients per month."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Lung Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "recurrent non-small cell lung cancer",
                        "stage IIIB non-small cell lung cancer",
                        "stage IV non-small cell lung cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "42",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Rebeccamycin 1 day",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "Patients receive rebeccamycin analogue IV over 1 hour on day 1.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: becatecarin"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Rebeccamycin 5 day",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: becatecarin"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "becatecarin",
                            "InterventionDescription": "Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Rebeccamycin 1 day",
                                    "Rebeccamycin 5 day"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "DEAE-rebeccamycin",
                                    "rebeccamycin analogue",
                                    "rebeccamycin analogue, tartrate salt"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Compare the efficacy, in terms of response rate, in patients with advanced or recurrent non-small cell lung cancer treated with rebeccamycin analogue",
                            "PrimaryOutcomeTimeFrame": "via 1 infusion vs 5 daily infusions every 3 weeks."
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically proven stage IIIB (with pleural effusions), IV, or recurrent non-small cell lung cancer with failure on 1 prior chemotherapy regimen\nMeasurable disease\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\nNot specified\n\nPerformance status:\n\n0-2\n\nLife expectancy:\n\nAt least 12 weeks\n\nHematopoietic:\n\nWBC at least 3,000/mm^3\nGranulocyte count at least 1,500/mm^3\nPlatelet count at least 100,000/mm^3\nHemoglobin greater than 10 g/dL\n\nHepatic:\n\nBilirubin no greater than 1.5 mg/dL\nAST and ALT less than 2 times normal\n\nRenal:\n\nCreatinine normal OR\nCreatinine clearance at least 60 mL/min\n\nCardiovascular:\n\nNo New York Heart Association class III or IV heart disease\n\nOther:\n\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNo concurrent illness that would preclude study\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\nNot specified\n\nChemotherapy:\n\nSee Disease Characteristics\nNo more than 1 prior chemotherapy regimen\nAt least 4 weeks since prior chemotherapy\n\nEndocrine therapy:\n\nNot specified\n\nRadiotherapy:\n\nNot specified\n\nSurgery:\n\nNot specified\n\nOther:\n\nNo concurrent combination antiretroviral therapy for HIV",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "StdAgeList": {
                    "StdAge": [
                        "Child",
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Afshin Dowlati, MD",
                            "OverallOfficialAffiliation": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Henry Ford Hospital",
                            "LocationCity": "Detroit",
                            "LocationState": "Michigan",
                            "LocationZip": "48202",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "LocationCity": "Cleveland",
                            "LocationState": "Ohio",
                            "LocationZip": "44106-5065",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000002289",
                            "ConditionMeshTerm": "Carcinoma, Non-Small-Cell Lung"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000002283",
                            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
                        },
                        {
                            "ConditionAncestorId": "D000001984",
                            "ConditionAncestorTerm": "Bronchial Neoplasms"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5236",
                            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
                            "ConditionBrowseLeafAsFound": "Non-Small Cell Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5230",
                            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4950",
                            "ConditionBrowseLeafName": "Bronchial Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            }
        }
    }
}